BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10625926)

  • 1. Telomerase as an anti-cancer target: current status and future prospects.
    Neidle S; Kelland LR
    Anticancer Drug Des; 1999 Aug; 14(4):341-7. PubMed ID: 10625926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere maintenance as a target for anticancer drug discovery.
    Neidle S; Parkinson G
    Nat Rev Drug Discov; 2002 May; 1(5):383-93. PubMed ID: 12120414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
    Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
    Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
    Goldkorn A; Blackburn EH
    Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase as an anti-cancer drug target: will it fulfil its early promise?
    Newbold RF
    Anticancer Drug Des; 1999 Aug; 14(4):349-54. PubMed ID: 10625927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase inhibitors.
    Rowley PT; Tabler M
    Anticancer Res; 2000; 20(6B):4419-29. PubMed ID: 11205282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.
    Kim JH; Kim JH; Lee GE; Kim SW; Chung IK
    Biochem J; 2003 Jul; 373(Pt 2):523-9. PubMed ID: 12689331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Telomere and telomerase in human cancer].
    Hiyama K; Hiyama E; Ishioka S; Yamakido M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.
    Kraemer K; Fuessel S; Schmidt U; Kotzsch M; Schwenzer B; Wirth MP; Meye A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3794-800. PubMed ID: 14506173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase as a therapeutic target for malignant gliomas.
    Komata T; Kanzawa T; Kondo Y; Kondo S
    Oncogene; 2002 Jan; 21(4):656-63. PubMed ID: 11850793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of telomerase inhibitors: the G-quartet approach.
    Mergny JL; Mailliet P; Lavelle F; Riou JF; Laoui A; Hélène C
    Anticancer Drug Des; 1999 Aug; 14(4):327-39. PubMed ID: 10625925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells.
    de Souza Nascimento P; Alves G; Fiedler W
    Oncol Rep; 2006 Aug; 16(2):423-8. PubMed ID: 16820926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere inhibition and telomere disruption as processes for drug targeting.
    Rezler EM; Bearss DJ; Hurley LH
    Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.